Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Jean-Marc Classe1, Frédéric Guyon2, Claire Falandry3

  • 1Département de chirurgie oncologique, institut de cancérologie de l'Ouest, Nantes, France.

Bulletin Du Cancer
|June 20, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of secondary cytoreductive surgery for relapsed ovarian low-grade serous carcinoma: a multicenter analysis from French TMRG network.

Journal of gynecologic oncology·2026
Same author

Response to Yu, Wang and Ge.

Journal of the National Cancer Institute·2026
Same author

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Translational oncology·2026
Same author

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.

Gynecologic oncology·2026
Same authorSame journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same author

Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial.

JAMA oncology·2026
Same journal

[Update: Evolution in the management of metastatic urothelial carcinomas].

Bulletin du cancer·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
See all related articles

Treatment for advanced ovarian cancer requires a multidisciplinary approach. Optimal surgery followed by chemotherapy (carboplatin, paclitaxel) and potentially bevacizumab is standard care.

Area of Science:

  • Oncology
  • Gynecologic Oncology
  • Clinical Practice Guidelines

Background:

  • Advanced epithelial ovarian cancer (EOC) necessitates a coordinated, multidisciplinary approach for optimal patient outcomes.
  • Current clinical practice requires validation of treatment strategies in multidisciplinary consultation meetings (RCP).

Purpose of the Study:

  • To outline recommendations for the clinical practice of managing advanced epithelial ovarian cancer.
  • To detail the multidisciplinary approach involving surgical and medical oncology teams.

Main Methods:

  • Pre-therapeutic assessment including histological diagnosis, tumor staging (imaging, laparoscopy), and operability evaluation.
  • Surgical management involving complete tumor resection via median laparotomy.
  • Adjuvant chemotherapy regimens and the potential role of bevacizumab.
Keywords:
Cancer de l’ovaireFirst lineMultidisciplinarityOvarian cancerPluridisciplinaritéPrise en charge initiale

Related Experiment Videos

Main Results:

  • Initial optimal surgery is feasible following comprehensive pre-therapeutic assessment.
  • Standard treatment involves complete surgical resection followed by six cycles of carboplatin and paclitaxel chemotherapy.
  • Bevacizumab may be used during adjuvant treatment and as maintenance therapy.

Conclusions:

  • Multidisciplinary consultation (RCP) is crucial for validating treatment strategies in advanced EOC.
  • If initial optimal surgery is not feasible, interval debulking surgery after induction chemotherapy is considered.
  • The described approach aims to optimize management for advanced epithelial ovarian cancer.